Investorideas.com newswire, defense and security sector

Wednesday, February 29, 2012

What is Bioagent Detection and How Is It Changing Our World?


Since the tragic attacks of September 11th, 2001, and the terrifying Amerithrax case, the world has become ever so aware of the threat of biological warfare and how very real this threat is. However, innovative companies like PositiveID Corporation (OTCBB: PSID) and their subsidiary MicroFluidic Systems have developed a bioagent detection device that will change how our government and military fight biowarfare.
So, what is bioagent detection anyway? Bioagent detection devices test the air for the presence of deliberately-released biological pathogens that are dangerous enough to be used as a biological weapon. Bacillus anthracis, perhaps the most commonly-known bioagent, causes Anthrax, a typically fatal disease. Because some of these hazardous agents can be made from readily-found ingredients, the need for solid protection against these types of deadly attacks continues to grow.
During the weeks immediately following the September 11 attacks, letters containing highlydeadly anthrax spores were sent via the postal system to several prominent news anchors and media offices, as well as two U.S. Senators. Five people were killed and 17 others were infected. For weeks, American citizens were terrorized by news reports of potentially-lethal exposure and warned of the deathly affects. Fearing for their safety, American demanded protection.
In response, the government formed BioWatch, a program to detect the release of airborne pathogens intended as an attack on major United States cities. The program was described as “the nation’s first early warning network of sensors to detect biological attack” and has included a system of filters located within the Environmental Protection Agency’s air filters. Collected data is analyzed by the Centers for Disease Control and Prevention and suspected threats are passed on to the Federal Bureau of Investigation.
However, criticism of the BioWatch program has brought some potential issues to the forefront. Many have expressed concerns about relying on the BioWatch system alone and some have pointed out specific points of possible failure in the system, from poor placement of filters in locations that are not optimal or are likely to incur bio attacks, to sizable gaps in coverage. Some noted that the BioWatch filters kill whatever pathogen has activated them, subsequently eliminating the possibility of further scientific testing. Others claim the current filters would be unable to detect indoor or underground bioagent releases, and would therefore, fail to protect our country in an attack.
Since the birth of BioWatch, the U.S. government and Department of Homeland Security have remain focused on keeping us safe from bio warfare attacks and bioterrorism. Millions have been spent on research supporting the development of better detection devices. America’s demand for a better answer is stronger than ever.
Luckily, PositiveID Corporation’s (“PositiveID”) subsidiary MicroFluidic Systems (“MFS”) developed a bio-threat detection device called M-BAND that will drastically change the world’s ability to defend against bioterrorism.
Developed over eight years, under contract for the Department of Homeland Security (DHS), MBAND is an early warning system designed to detect the presence of intentionally-released aerosolized biological agents. For up to 30 days, M-BAND uses a biocell monitor, running autonomously, continuously collecting samples and analyzing the air. Designed to detect bacteria, viruses, and toxins, these machines can provide results within a mere three hours. Typically placed in high-traffic areas and networked together, M-BAND devices effectively monitor for air-borne pathogens by testing the air every 30 minutes and delivering results through a secure wireless network to a central location for extensive analysis.
After eight years of development, M-BAND offers a real solution. By providing real-time data, M-BAND provides awareness and protection against potential biological warfare attack. Furthermore, M-BAND can be remotely configured to test for all three pathogen types, both simultaneously at programmable intervals or any one in particular, including DNA-based pathogens, with or without either RNA-based organisms or toxins.
Among the bioagents that M-BAND can identify are strains of Bacillus anthracis, also known as anthrax, Yersinia pestis, responsible for causing Black Death and bubonic plague, Francisella tularensis, which causes tularemia or rabbit fever, Burkholderia mallei, which causes Glanders, and Burkholderia pseudomallei, the cause of melioidosis. Because these agents can kill so many people so quickly, an effective warning system is necessary and more important than ever to implement effective quarantine procedures as a line of defense.
The Department of Homeland Security has allocated $3 billion in the budget for bioaresol monitors to setup a network of early warning systems across the country. Luckily, among the large companies and organizations involved with bioagent detection, the unlikely underdog could save the day. The small-but-mighty PositiveID Corporation with M-BAND, an amazing biocell device, is changing the world of bioagent detection.
In a recent press release, PositiveID announced their upcoming presentation of their bioagent detection device called M-BAND at the 10th Annual American Society for Microbiology Biodefense and Emerging Diseases Research Meeting, scheduled to take place from February 26-29, 2012, in Washington, DC. Although smaller than some defense companies, PositiveID Corporation is making big waves on the BioWatch scene. By exhibiting with The Boeing Company, PositiveID stands to change the way the world fights bio warfare and bioterrorism.
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the penny stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in small cap and micro cap stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visithttp://www.smallcapvoice.com/services.html.
IMPORTANT DISCLAIMER – PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.
Contact:
Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
http://www.smallcapvoice.com

Security Stock Investor Alert: Magal Security Systems (NASDAQ: MAGS) Closes up over 14%

New York, NY - February 29, 2012 - www.InvestorIdeas.com, a global investor research portal, specializing in sector research for independent investors, issues a trading alert for security stock, Magal Security Systems Ltd. (NasdaqGM: MAGS) for market close February 28th. The stock ended trading at $4.79, up 0.59(14.05%) 4:00PM EST on over 187,000 shares.
Last news from the Company was January 23rd that it had won a US$2.1 million contract to supply and install multi-layer Perimeter Intrusion Detection Systems (PIDS) for two new high security prisons in Latin America.
Investorideas.com Newswire

Magal S3 is a leading international provider of security, safety and site management solutions and products. Over the past 40 years, Magal S3 has delivered tailor-made solutions and turnkey projects to hundreds of satisfied customers in over 80 countries.
http://www.magal-s3.com
Research defense and security stocks with the Investorideas.com defense and security stocks Directory:
http://www.investorideas.com/Companies/HomelandDefense/ Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/ #!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/ Investorideas
Follow Investorideas.com on Google Plus https://plus.google.com/ 116622008917768549777
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/ Resources/Newsletter.asp
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more. Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411 - Source - www.Investorideas.com

Tuesday, February 21, 2012

Biodefense Stock News: PositiveID (OTCBB:PSID) to Present M-BAND at ASM Biodefense and Emerging Diseases Research Meeting February 26-29

DELRAY BEACH, Fla., February 21, 2012 - (Investorideas.com Newswire) PositiveID Corporation's (OTCBB: PSID) subsidiary MicroFluidic Systems (“MFS”), a developer of molecular diagnostic systems, announced today it will present its M-BAND (Microfluidics-based Bioagent Autonomous Networked Detector) system at the 10 th Annual American Society for Microbiology (“ASM”) Biodefense and Emerging Diseases Research Meeting, to be held February 26-29, 2012, in Washington, DC at the Omni Shoreham Hotel. PositiveID will jointly exhibit M-BAND with The Boeing Company (NYSE:BA) and Hamilton Sundstrand.
M-BAND, developed under contract for the Department of Homeland Security by MFS, is an early warning system designed to detect the intentional release of aerosolized biological agents . It runs autonomously for up to 30 days, continuously analyzing air samples, typically in high-traffic areas, for the detection of bacteria, viruses, and toxins with results in as little as three hours. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments in aggregate. Designed with a high level of operational flexibility, M-BAND can be remotely set to detect for DNA-based pathogens alone, with or without either RNA-based organisms or toxins, or for all three types of pathogens simultaneously at remotely programmable intervals.
According to the ASM, approximately 1,000 leaders and decision makers in the field of biodefense will participate in the Biodefense and Emerging Diseases conference to discuss the critical research necessary to defend against the growing threat of bioterrorism and shape the future of the biodefense research agenda.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID will present its M-BAND system at the ASM Biodefense and Emerging Diseases Research Meeting; the likelihood that PositiveID will jointly exhibit M-BAND with The Boeing Company and Hamilton Sundstrand; the likelihood that approximately 1,000 leaders and decision makers in the field of biodefense will participate in the Biodefense and Emerging Diseases conference to discuss the critical research necessary to defend against the growing threat of bioterrorism and shape the future of the biodefense research agenda; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize M-BAND; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Published at the Investorideas.com Newswire and syndicated blogs
Learn more about PSID at Investorideas.com
http://www.investorideas.com/CO/PSID/
Disclaimer /Disclosure : Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and  company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/

Thursday, February 16, 2012

Chairman and CEO of PositiveID (OTCBB: PSID) Discusses Catalysts for 2012 in Diabetes Market and Homeland Security Market

Chairman and CEO of PositiveID (OTCBB: PSID) Discusses Catalysts for 2012 in Diabetes Market and Homeland Security Market


New York, NY- February 16, 2012 – (Investorideas.com Newswire) Medical Technology Stock news alert: Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Medical technology stock, PositiveID Corporation (OTCBB: PSID). Mr. William J. Caragol, Chairman and Chief Executive Officer discusses the catalysts for 2012 for both its diabetes management technologies and its Homeland Security airborne bio-threat detection technology.

Q: Investorideas.com

We noted that late last year the Department of Homeland Security (“DHS”) Office of Health Affairs began the procurement process for the deployment of an autonomous biodetection system called BioWatch Gen-3. Can you give investors insight as to the potential 2012 opportunities for the Company’s airborne bio-threat detection technology (M-BAND) in this process?



A: Mr. William J. Caragol, Chairman and Chief Executive Officer

Our MicroFluidic Systems (“MFS”) subsidiary, is a leader in biothreat detection technologies and molecular diagnostic systems, and developed its M-BAND technology under contract from DHS over the past eight years. We believe our M-BAND, a Microfluidics-based Bioagent Autonomous Networked Detector, is one of only two technologies that is compatible with DHS’ procurement for Gen-3 of Biowatch, which has a total value of more than $3 billion over approximately five years, as described by the DHS in their draft RFP. This opportunity, relative to the provision of biodetectors and the renewables, represents a very significant opportunity for PositiveID.



Q: Investorideas.com

With your three diabetes management technologies, Easy Check™, GlucoChip™ and iglucose™, can you give investors a quick summary of some of the recent key developments announced by the Company and some of the key drivers for 2012?



A: Mr. William J. Caragol, Chairman and Chief Executive Officer

We continue to make significant progress with each of our diabetes management products. Starting with Easy Check, our non-invasive breath glucose detection device, we completed a prototype device in 2011 and achieved positive preliminary results in early testing that are within industry standards. We recently announced the initiation of a clinical study of Easy Check with Schneider Children’s Medical Center in Israel, led by a world leading endocrinologist. We expect to have results from that study later this year.



Moving on to GlucoChip, a continuous glucose-sensing microchip, we have completed Phase II development and proved a stable and reproducible, closed-cycle continuous glucose sensor that functions in human blood. We also recently provided an update on a biotransport study we are conducting with the Diabetes Research Institute at the University of Miami, which has yielded positive preliminary results. We will continue to provide updates on our progress over the next few months. As those results develop, we will look to work with a partner to incorporate the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of a radio frequency identification microchip to complete development of GlucoChip



Last but not least, we received FDA clearance for iglucose, which is a mobile health system for diabetes management, in late 2011, and are now preparing to roll-out this product with health insurers and home-healthcare providers. As we look ahead to the rest of 2012, we expect that the initial roll-out of iglucose in the first half of the year will be followed by larger orders and partnering agreements.



Q: Investorideas.com

Your technology takes management of diabetes to the clouds literally. With the iglucose technology, the data stored in the diabetes management portal can be shared automatically by text messaging or email. How significant a breakthrough is this for family members, caregivers and healthcare professionals and most importantly, the patient?



A: Mr. William J. Caragol, Chairman and Chief Executive Officer

The value proposition of iglucose is to provide an individual with diabetes flexibility and wireless connectivity to better manage their condition and stay in touch with loved ones. With iglucose, an individual no longer has to keep manual logbooks – iglucose automatically pulls the data from a glucometer and sends it to the cloud. Patients can continue to use their preferred blood glucose meter and there is no cell phone or data plan required. iglucose simplifies diabetes management by automating the process of providing blood glucose readings to healthcare professionals for more informed communication and treatment decisions. iglucose also provides peace of mind for family members that their loved ones are testing and what their values are.



Q: Investorideas.com

Easy Check is your non-invasive breath glucose detection device that measures the level of acetone in a patient's exhaled breath and correlates that acetone level to a measure of blood glucose. With a rapid growth of diabetes in children how significant is it to have a technology that could eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading?



A: Mr. William J. Caragol, Chairman and Chief Executive Officer

Being able to provide the diabetes community with a non-invasive method of testing their blood sugar is often called the “Holy Grail” of diabetes management. Certainly for children, offering non-invasive testing is even more important and appealing. Many times, people with diabetes do not test as often as prescribed by their physician due to the pain and inconvenience of drawing blood.



About PositiveID Corporation

PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.



Statements about PositiveID's future expectations, including the likelihood that its M-BAND is one of only two technologies that is compatible with DHS’ procurement for Gen-3 of Biowatch, which has a total value of more than $3 billion over approximately five years, as described by the DHS in their draft RFP; the likelihood that this opportunity, relative to the provision of biodetectors and the renewables, represents a very significant opportunity for PositiveID; the likelihood that PositiveID will continue to make significant progress with each of its diabetes management products; the likelihood that PositiveID will have results from its Easy Check clinical study later this year; the likelihood that PositiveID will continue to provide updates on its progress with GlucoChip over the next few months; the likelihood that as those results develop, PositiveID will look to work with a partner to incorporate the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of a radio frequency identification microchip to complete development of GlucoChip; the likelihood that PositiveID is now preparing to roll-out this product with health insurers and home-healthcare providers; the likelihood that the initial roll-out of iglucose in the first half of the year will be followed by larger orders and partnering agreements; the likelihood that iglucose simplifies diabetes management by automating the process of providing blood glucose readings to healthcare professionals for more informed communication and treatment decisions; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully complete development and commercialize Easy Check, GlucoChip and iglucose; the likelihood that PositiveID will participate in BioWatch Gen-3; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.



Contact:

Allison Tomek

561-805-8000

atomek@positiveidcorp.com



Learn more about PSID at Investorideas.com

http://www.investorideas.com/CO/PSID/



About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas



Get Free investor news and stock alerts

Sign Up: http://www.investorideas.com/Resources/Newsletter.asp



Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30, 2012. Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile .More info:www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894



Contact Investorideas.com 800 665 0411

Investorideas.com newswire